跳至主要内容
临床试验/NCT05424978
NCT05424978招募中不适用

Application of Standardized Green Channel Treatment System for Ischemic Stroke in Xi 'an

Xi'an No.3 Hospital1 个研究点 分布在 1 个国家目标入组 3,600 人开始时间: 2022年6月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
3,600
试验地点
1
主要终点
Rate of function independent

研究概览

简要总结

Objective: To observe the practical application of the standardized green channel treatment system for stroke in Xi 'an in the real world. Methods: Clinical data and information of patients with acute ischemic stroke who received standardized green channel treatment for stroke were collected, and a multicenter observational clinical study was carried out in the real world to evaluate the prognosis, mortality, incidence of asymptomatic and symptomatic cerebral hemorrhage, incidence of pneumonia, and recurrence rate of stroke after 90 days.

详细描述

The standardized green channel treatment system for acute ischemic stroke includes: Triage nurse triage timely, rapid assessment emergency doctor, suspected stroke the green channel, immediately start in the green channel of stroke accompanied by doctors and nurses stroke patients improve CT examination, intravenous thrombolysis or CT room, emergency room if considering large vascular lesions and the onset time in 6 hours, and rapidly to international for endovascular treatment, if the onset time of more than 6 hours, Rapid evaluation of ischemic penumbra and vascular occlusion by multi-mode imaging. If there are indications for endovascular treatment, go to the cath room for endovascular treatment as soon as possible.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 100 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •18 years old;
  • •Consistent with the diagnosis of acute ischemic stroke;
  • •24 hours from onset to enrollment;
  • •Informed consent

排除标准

  • •Patients who refuse to receive intravenous thrombolysis or intravascular intervention (including intravascular mechanical thrombolysis and arterial thrombolysis);
  • •Stroke patients caused by brain tumor, brain trauma and blood diseases;
  • •Those with a history of stroke and sequelae affecting the outcome assessment, namely, mRS 2 points before the onset of this stroke;
  • •Combined with claudication osteoarthritis rheumatoid arthritis gout arthritis and other limb dysfunction and affect the neurological function examination;
  • •Patients with severe hepatic and renal insufficiency (Note: Hepatic insufficiency refers to ALT or AST values greater than 2 times the upper normal limit; Renal insufficiency refers to blood creatinine value greater than 2 times the normal upper limit);
  • •Suffering from other serious life-threatening diseases with an expected survival time of less than 3 months;
  • •Other diseases that limit neurological function evaluation or affect patient follow-up;
  • •A woman planning to be pregnant or breastfeeding;
  • •Currently participating in other clinical trials;
  • •Refuse to participate in the registration of investigators

结局指标

主要结局

Rate of function independent

时间窗: 90 days after onset

Rate of modified Rankin Scale(mRS) score less than 3 at 90 days

次要结局

  • Rate of mortality(90 days after onset)
  • Rate of stroke recurrence(90 days after onset)
  • Rate of cerebral hemorrhage and pneumonia(During hospitalization.)

研究者

发起方
Xi'an No.3 Hospital
申办方类型
Other Gov
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验